H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
Express News | HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Caribou Biosciences: A Strong Buy on Solid Financials and Promising Trials
Express News | Caribou Biosciences Appoints Tina Albertson, Md, Phd, as Chief Medical Officer
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
Bank of America Securities Keeps Their Buy Rating on Caribou Biosciences (CRBU)
Express News | Caribou Biosciences Inc : BofA Global Research Cuts Price Objective to $15 From $17
RBC Capital Reiterates Outperform on Caribou Biosciences, Maintains $14 Price Target
Express News | Caribou Biosciences Inc : Leerink Partners Cuts Target Price to $9 From $10
Caribou Bioscience GAAP EPS of -$0.42 Beats by $0.04, Revenue of $3.46M Beats by $0.42M
Caribou Biosciences | 10-Q: Q2 2024 Earnings Report
Press Release: Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Small-Cap Stocks Are Having a Moment. Check Out the 10 Biggest Winners.
Strategic Focus and Financial Runway Extension Bolster Caribou Biosciences' Buy Rating
Caribou Cuts 12% of Workforce, Extends Cash Runway Into 2H 2026
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
Will Caribou Biosciences (NASDAQ:CRBU) Spend Its Cash Wisely?
Express News | HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target